Who is sponsoring NCT05648734?

NCT05648734 is sponsored by Mansoura University.

What drugs are being tested in NCT05648734?

Interventions in NCT05648734: Corticosteroids alone, Corticosteroids + Colchicine, Corticosteroids + Pirfenidone, Corticosteroids + Colchicine + Pirfenidone for ≥ 14 days.

What condition does NCT05648734 study?

NCT05648734 studies Post-COVID-19 Syndrome, Lung Fibrosis.

Is NCT05648734 still recruiting?

NCT05648734 is currently completed. Last updated 13 December 2022.

Last reviewed 2022-12-13 · How we verify

NCT05648734

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anti-Inflammatory and Anti-Fibrotic Drugs in Post COVID-19 Pulmonary Fibrosis

Completed Last updated 13 December 2022

What this trial tests

trial testing Corticosteroids alone in Post-COVID-19 Syndrome in 200 participants. Completed in 15 September 2022.

Timeline

10 March 2022

Primary endpoint
15 June 2022

15 September 2022

Quick facts

Lead sponsor	Mansoura University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	200
Start date	10 March 2022
Primary completion	15 June 2022
Estimated completion	15 September 2022
Sites	1 location across Egypt

Drugs / interventions tested

Corticosteroids alone — full drug profile →
Corticosteroids + Colchicine — full drug profile →
Corticosteroids + Pirfenidone — full drug profile →
Corticosteroids + Colchicine + Pirfenidone for ≥ 14 days — full drug profile →

Conditions studied

Post-COVID-19 Syndrome — all drugs for Post-COVID-19 Syndrome →
Lung Fibrosis — all drugs for Lung Fibrosis →

Sponsor

Mansoura University

Who can join

18 and older, any sex, with Post-COVID-19 Syndrome or Lung Fibrosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this study we aim to evaluate the radiological and functional changes in post-acute covid-19 pulmonary fibrosis patients in relation to anti-inflammatory and/or antifibrotic drugs prescribed during and after covid-19 pneumonia.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Antifibrotic Drugs against Idiopathic Pulmonary Fibrosis and Pulmonary Fibrosis Induced by COVID-19: Therapeutic Approaches and Potential Diagnostic Biomarkers.
Perez-Favila A, Garza-Veloz I, Hernandez-Marquez LDS, Gutierrez-Vela EF, et al · · 2024 · cited 9× · PMID 38338840 · DOI 10.3390/ijms25031562
Advances in Selenium and Related Compounds Inhibiting Multi-Organ Fibrosis.
Xiao X, Huang G, Yu X, Tan Y. · · 2025 · cited 3× · PMID 39830783 · DOI 10.2147/dddt.s488226
Nanotherapeutic Approaches to Treat COVID-19-Induced Pulmonary Fibrosis.
Kanvinde S, Deodhar S, Kulkarni TA, Jogdeo CM. · · 2023 · cited 1× · PMID 37218751 · DOI 10.3390/biotech12020034
Nano-Therapeutic Approaches to Treat COVID Induced Pulmonary Fibrosis
Kanvinde S, Deodhar S, Kulkarni TA, Jogdeo CM. · · 2023 · DOI 10.20944/preprints202303.0472.v1

Verify or expand the search:

Other trials of Corticosteroids alone

Trials testing the same drug.

NCT06780462 — Randomized Controlled Multicenter Study Comparing Steroid Therapy Plus Anticoagulants to Steroid Therapy Alone in Deep V · Phase 3 · recruiting

Other Mansoura University trials

Trials by the same sponsor.

NCT05785377 — Neostigmine as an Adjuvant in Tranversus Abdominis Plane (TAP) Block in Cesarean Section Under Spinal Anesthesia · NA · not yet recruiting
NCT07509567 — Conventional Palatal Crib Versus Bonded Spurs for Anterior Open Bite Treatment · NA · not yet recruiting
NCT07393178 — Efficacy & Safety of High Power vs. Low Power Holmium Laser in Mini-PCNL for Large Renal Stones · NA · not yet recruiting
NCT07436182 — Mitochondrial Redox Modulation in Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial Comparing Imeglimin vs. · Phase 4 · not yet recruiting
NCT07534943 — Effectiveness of Oleanolic Acid as Intracanal Medicament on Infectious/Inflammatory Contents in Teeth With Apical Period · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05648734 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mansoura University
Last refreshed: 13 December 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05648734.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing